H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on aTyr Pharma (ATYR – Research Report) today and set a price target of $35.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily focusing on the promising advancements in aTyr Pharma’s clinical trials. The company is financially robust, ending the first quarter of 2025 with $78.8 million in cash, which positions it well to continue its research and development activities. The anticipated topline Phase 3 EFZO-FIT data readout in the third quarter of 2025 is a significant milestone that could potentially enhance the company’s visibility among investors.
Additionally, aTyr Pharma’s ongoing Phase 2 EFZO-CONNECT study for systemic sclerosis-associated interstitial lung disease (SSc-ILD) is another critical factor. This trial is designed to evaluate the efficacy, safety, and tolerability of efzofitimod, with interim data expected in the second quarter of 2025. The study’s progress and the potential expansion of efzofitimod’s applications underscore the company’s strategic growth prospects, further supporting Pantginis’s positive outlook on the stock.
In another report released yesterday, Wells Fargo also reiterated a Buy rating on the stock with a $17.00 price target.